Meglumine antimoniate contraindications: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Meglumine antimoniate}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second E...")
 
mNo edit summary
 
Line 3: Line 3:
{{CMG}}
{{CMG}}


==Contraindications==


 
Severe kidney, heart or liver disorders.<ref>{{Cite web  | last =  | first =  | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher =  | date =  | accessdate = }}</ref>
 
 
<ref>{{Cite web  | last =  | first =  | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 03:41, 7 January 2014

Meglumine Antimoniate
GLUCANTIM® WHO Prescribing Information
Description
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Contraindications

Severe kidney, heart or liver disorders.[1]

References

  1. "WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate".

Adapted from the FDA Package Insert.